4CPS-255 Clinical experience of ceftaroline use in a third level hospital

Martínez, Álvaro; Lacunza, Rafael Huarte; Rello, A Pinilla; Poderoso, L Cazorla; Moreno, Mireia; Pérez, A López; Pascual, Jordi; Sazatornil, Abad

doi:10.1136/ejhpharm-2021-eahpconf.87

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table, Supplemental Digital Content 2, http://links.lww.com/INF/F480 summarizes included articles. Overall, 13 articles were case reports, [10][11][12][13][14][15][16][17][18][19][20][21][22] 7 articles presented observational data of multiple patients with CNS infections treated with ceftaroline [23][24][25][26][27][28][29] and 2 articles presented prospective single-arm clinical trials evaluating pharmacokinetics/pharmacodynamics of ceftaroline in neurosurgical patients with intracranial shunts. 30,31 We identified 92 unique patients who were described, of whom 2 were pediatric patients (<21 years old), 20,22 one of whom was <6 months old.…”

Section: Resultsmentioning

confidence: 99%

“…Several studies reported adverse events associated with ceftaroline use during the treatment of CNS infections. A common adverse effect attributed to ceftaroline was reversible myelosuppression, 11,13,24,[26][27][28][29] and granulocyte-colony stimulating factor was occasionally needed to boost neutrophil counts. 11,13 Additional hematologic adverse effects included warm autoimmune hemolytic anemia after treatment with vancomycin and ceftaroline.…”

Section: Adverse Effectsmentioning

confidence: 99%

See 1 more Smart Citation

Ceftaroline for Central Nervous System Infections: Case Report of a Young Infant, and Scoping Review

Urbach,

Sileo,

Lerma

et al. 2024

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Background: Managing health care acquired and device-associated intracranial infections in young children can be challenging given adverse antibiotic side effects and difficulties in achieving adequate central nervous system (CNS) antibiotic concentrations. Ceftaroline is a cephalosporin with a favorable safety profile and activity against methicillin-resistant Staphylococci and several Gram-negative organisms. Published data on the use of ceftaroline for CNS infections in children and adults are limited. Methods: We describe a 2-month-old infant with ventriculo-subgaleal shunt-associated methicillin-resistant Staphylococcus epidermidis ventriculitis, which was successfully treated with ceftaroline, in addition to vancomycin and rifampin. We conducted a scoping review of English-language literature retrieved from PubMed, EMBASE and Web of Science that assessed the use of ceftaroline for CNS infections. Results: We identified 22 articles for inclusion in our review, which described 92 unique patients, of whom 2 were <21 years old. Ceftaroline was commonly used in conjunction with other antibiotics to treat infections caused by Staphylococcus aureus, coagulase-negative Staphylococci and Streptococcus pneumoniae. Most case reports described clinical success with ceftaroline, though small case series and cohort studies yielded mixed efficacy assessments. Adverse effects attributed to ceftaroline were rare and included reversible myelosuppression, eosinophilia, hepatotoxicity and nephrotoxicity. Pharmacokinetic/pharmacodynamic studies suggested similar CNS penetration through inflamed meninges as other beta lactam antibiotics. Conclusions: We identified a growing body of published evidence supporting the use of ceftaroline in combination with other agents for the treatment of CNS infections. In absence of clinical trials, additional real-world data are needed to define the efficacy and safety of ceftaroline for children and adults with CNS infections.

show abstract